Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute Of Molecular Biology And Genetics, |
RCV001376155 | SCV001548553 | uncertain significance | X-linked Emery-Dreifuss muscular dystrophy | 2021-03-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001376155 | SCV002247671 | likely benign | X-linked Emery-Dreifuss muscular dystrophy | 2023-10-03 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001376155 | SCV002790463 | uncertain significance | X-linked Emery-Dreifuss muscular dystrophy | 2021-10-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003365355 | SCV004054997 | uncertain significance | Cardiovascular phenotype | 2023-07-17 | criteria provided, single submitter | clinical testing | The p.S58F variant (also known as c.173C>T), located in coding exon 2 of the EMD gene, results from a C to T substitution at nucleotide position 173. The serine at codon 58 is replaced by phenylalanine, an amino acid with highly dissimilar properties. This alteration has been reported in an Emery-Dreifuss muscular dystrophy cohort; however, clinical details were limited (Kovalchuk T et al. Front Cardiovasc Med, 2021 May;8:668231). Based on data from gnomAD, the T allele has an overall frequency of 0.0018% (3/171015) total alleles studied, with 2 hemizygote(s) observed. The highest observed frequency was 0.0075% (2/26696) of Latino alleles. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |